CD19-directed chimeric antigen receptor (CAR) T-cell therapy has achieved high remission rates in patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL), representing a major breakthrough in leukemia treatment. Despite these impressive initial responses, disease relapse remains a common and unresolved challenge, limiting long-term disease-free survival for many patients.

To improve post-remission outcomes, multiple centers, including GoBroad Healthcare Group–affiliated institutions, have explored consolidation strategies following CD19 CAR-T therapy. These approaches have included allogeneic hematopoietic stem cell transplantation (allo-HCT) and sequential infusion of CD22-targeted CAR T cells. While such post-CAR-T consolidations have extended remission duration in a subset of patients, relapse continues to occur in some cases, and the underlying biological drivers of treatment failure remain poorly defined.

Genetic risk factors may play a critical role in determining long-term outcomes after CAR-T therapy. TP53 mutation is a well-established predictor of treatment resistance and poor prognosis in childhood B-ALL when treated with conventional chemotherapy. TP53-deficient leukemia cells exhibit marked genomic instability, enabling rapid genomic evolution and adaptation under therapeutic pressure. This plasticity allows malignant cells to survive cytotoxic stress and contributes to relapse across multiple treatment modalities.

Previous studies from our group and others have shown that CAR T-cell therapy can overcome traditional high-risk genetic features, including TP53 mutation, and induce deep remissions in patients who would otherwise have poor responses to standard therapies. These findings suggest that CAR-T therapy may partially bypass the immediate negative impact of adverse genomic alterations. However, whether TP53 mutation and other genetic abnormalities influence long-term outcomes—such as disease-free survival and relapse risk—after CAR-T–based treatment remains an open and clinically important question.

Understanding the interaction between genetic instability, CAR-T–mediated immune pressure, and leukemia evolution is essential for optimizing treatment strategies in r/r B-ALL. Identifying genetic predictors of relapse after CAR-T therapy may help refine patient stratification, guide post-CAR-T consolidation decisions, and inform the development of combination or sequential therapies aimed at preventing disease recurrence.

This line of investigation highlights the need to integrate genomic profiling with cellular immunotherapy in the management of high-risk B-ALL. By advancing research into the genetic determinants of CAR-T therapy durability, GoBroad Healthcare Group continues to support precision medicine approaches designed to improve long-term outcomes for children and adults with relapsed or refractory leukemia.

Refer to the original: https://doi.org/10.1038/s41375-020-0831-z